v3.25.0.1
Share-Based Payments - Additional Information (Details)
€ / shares in Units, $ / shares in Units, € in Millions
1 Months Ended 3 Months Ended 8 Months Ended 12 Months Ended
Aug. 09, 2024
EUR (€)
€ / shares
May 17, 2021
€ / shares
May 12, 2021
€ / shares
Feb. 13, 2020
$ / shares
Aug. 19, 2019
Nov. 15, 2018
€ / shares
Aug. 18, 2017
USD ($)
$ / shares
Dec. 31, 2024
EUR (€)
shares
€ / shares
May 31, 2024
€ / shares
May 31, 2023
€ / shares
May 31, 2022
EUR (€)
€ / shares
May 31, 2021
EUR (€)
Feb. 29, 2020
€ / shares
Sep. 30, 2019
Apr. 03, 2019
€ / shares
Dec. 31, 2024
EUR (€)
shares
Dec. 31, 2024
EUR (€)
shares
Dec. 31, 2024
EUR (€)
shares
€ / shares
Dec. 31, 2024
USD ($)
shares
Dec. 31, 2023
EUR (€)
shares
€ / shares
Dec. 31, 2022
EUR (€)
shares
Dec. 31, 2021
Disclosure of terms and conditions of share-based payment arrangement [line items]                                            
Share-based payments                                   € (154.5)   € (766.2) € (51.8)  
Cash outflow to tax authority                                   9.9        
Liabilities from share-based payment arrangements               € 26.6               € 26.6 € 26.6 € 26.6   € 29.0    
Option term                                   4 years 4 years      
Exercise price (in euros per share) | € / shares   € 179.83 € 178.29               € 146.40   € 28.32                  
Weighted average share price (in euros per share) | € / shares                                   € 83.45   € 96.49    
Expense recognized for employee services received                                   € 100.9   € 51.4 € 108.0  
LTI Program                                            
Disclosure of terms and conditions of share-based payment arrangement [line items]                                            
Vesting period                                       4 years 4 years 4 years
BioNTech 2024 North America Employee Participation Plan - RSUs                                            
Disclosure of terms and conditions of share-based payment arrangement [line items]                                            
Vesting period                                   4 years 4 years      
Granted (in shares)               47,115 356,757                          
Granted (in euros per share) | € / shares               € 93.00 € 93.00                          
Forfeited (in shares)                                 24,284          
Shares outstanding (in shares)               379,588               379,588 379,588 379,588        
Vesting percentage                                   25.00% 25.00%      
BioNTech 2024 North America Employee Participation Plan - PSUs                                            
Disclosure of terms and conditions of share-based payment arrangement [line items]                                            
Granted (in shares)                 34,481                          
Granted (in euros per share) | € / shares                 € 93.00                          
Forfeited (in shares)                                 2,915          
Shares outstanding (in shares)               31,566               31,566 31,566 31,566        
InstaDeep RSU Program Employees                                            
Disclosure of terms and conditions of share-based payment arrangement [line items]                                            
Vesting period                                   4 years 4 years      
Granted (in shares)                 160,997                          
Granted (in euros per share) | € / shares                 € 92.08                          
Shares outstanding (in shares)               120,748               120,748 120,748 120,748        
Vesting percentage                                   25.00% 25.00%      
Target incentive amount               € 15.0               € 15.0 € 15.0 € 15.0        
Number of option rights vested (in shares)                               40,249            
Expense recognized for employee services received                               € 2.1            
BioNTech 2020 Restricted Stock Unit Plan For North America Employees                                            
Disclosure of terms and conditions of share-based payment arrangement [line items]                                            
Vesting period                                           4 years
Vesting percentage                                           25.00%
Cash outflow for share based payment exercise                                   13.9   € 10.0 € 9.4  
Liabilities from share-based payment arrangements               11.2               11.2 11.2 11.2   14.4    
Management Board Grant                                            
Disclosure of terms and conditions of share-based payment arrangement [line items]                                            
Liabilities from share-based payment arrangements               2.8               2.8 2.8 € 2.8   € 2.1    
Awards paid at end of month settled                                   50.00% 50.00%      
Awards paid one year after reaching target                                   50.00% 50.00%      
Option rights vesting period (in years)                                   4 years 4 years      
Option rights exercisable period (in years)                           10 years       4 years 4 years      
Percentage of exercise price increase (as a percent)                                   7.00% 7.00%      
Threshold amount of dividend by number of shares outstanding immediately following initial public offering                                   € 8,500.0        
Percentage of target share price applicable for prior twelve month period (as a percent)                                   107.00% 107.00%      
Reclassification for share-based payment arrangement                     € 3.3 € 1.1                    
Price of ADS as a percentage of exercise price, maximum (as a percent)                         800.00%                  
Maximum economic benefits of options exercised | $                                     $ 246.24      
Exercise price (in euros per share) | (per share)       $ 30.78           € 104.86                        
Options outstanding, weighted-average expected life (in years)                                       4 years 1 month 6 days    
Liability related to the phantom option awards               5.1               5.1 5.1 € 5.1   € 3.6    
Management Board Grant | Prof. Ugur Sahin, M.D.                                            
Disclosure of terms and conditions of share-based payment arrangement [line items]                                            
Maximum cash payment               20.0               20.0 20.0 20.0        
Management Board Grant | All Other Members                                            
Disclosure of terms and conditions of share-based payment arrangement [line items]                                            
Maximum cash payment               € 10.0               € 10.0 € 10.0 € 10.0        
Chief Executive Officer Grant | Ordinary shares | Employee Stock Ownership Plan 2019                                            
Disclosure of terms and conditions of share-based payment arrangement [line items]                                            
Number of option rights vested (in shares) | shares                                         4,374,963  
Exercise price in translation for IPO (in dollar per share and euro per share) | € / shares € 13.74                                          
Weighted average share price (in euros per share) | € / shares € 73.68                                          
Intrinsic value of exercised options € 259.5                                          
Applicable wage taxes and social security contributions resulting from and withheld upon exercise € 123.2                                          
Employee Stock Ownership Plan                                            
Disclosure of terms and conditions of share-based payment arrangement [line items]                                            
Percentage of exercise price increase (as a percent)         7.00%   8.00%                              
Price of ADS as a percentage of exercise price, maximum (as a percent)             800.00%                              
Maximum economic benefits of options exercised | $             $ 240.00                              
Exercise price (in euros per share) | € / shares           € 10.14                 € 15.03              
Effective exercise price maximum (in dollars per share) | $ / shares             $ 30.00                              
Minimum strike price (as a percent)         28.00%   32.00%                              
Cash-settled option rights, exercised (in shares) | shares                                   7,725 7,725 39,785    
Share options outstanding (in shares) | shares               10,074               10,074 10,074 10,074   17,799 57,584  
Employee Stock Ownership Plan | Ordinary shares                                            
Disclosure of terms and conditions of share-based payment arrangement [line items]                                            
Vesting period             4 years                              
Option rights exercisable period (in years)             4 years                              
Cash-Settled Share-Based Payment Arrangement | Employee Stock Option Plan                                            
Disclosure of terms and conditions of share-based payment arrangement [line items]                                            
Liabilities from share-based payment arrangements               € 5.0               € 5.0 € 5.0 € 5.0   € 8.5    
Weighted average share price (in euros per share) | € / shares                                   € 92.70        
Exercise price of phantom options granted (in euro per share) | € / shares                                       € 10.14    
Cash-settled option rights, exercised (in shares) | shares                                   50,748 50,748      
Cash outflow                                   € 3.8        
Share options outstanding (in shares) | shares               58,903               58,903 58,903 58,903